The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
Researchers at the NCI have developed a treatment for prostate and breast cancer using multivalent peptides derived from TARP, the T cell receptor gamma alternate reading frame protein. These immunogenic peptides from TARP elicit an immune response, triggering T cells to kill only the cancer cells within a patient. NCI seeks licensees or co-development partners to commercialize this invention.
Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis. The National Institute on Aging's Immunotherapeutics Unit, is seeking parties interested in licensing or co-development of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape.
Scientists at the National Cancer Institute (NCI) have developed an engineered bacteriophage lambda () vector for displaying antigens to be used as a vaccine in treatment of cancers and infectious diseases. The NCI seeks licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.
Researchers at the NCI developed immunologically active peptides of the human endogenous retrovirus ERVMER34-1 that bind to human leukocyte antigen A2 (HLA-A2) and elicit multifunctional T cell responses in cancer patients. These peptides and associated agonist epitopes can be used to develop cancer vaccines for the prevention and/or treatment of several cancer types. NCI seeks licensees or co-development partners to commercialize this invention.
Researchers at the National Cancer Institute (NCI) have developed a dendritic cell vaccine for treating multiple cancer types. The NCI seeks licensing and/or co-development research collaborations to bring this invention to the public.